Stockscreener 앱 받기
1.18
6.35%
-0.08
시간 외 거래:
1.21
0.03
+2.54%
전일 마감가:
$1.26
열려 있는:
$1.25
하루 거래량:
1.60M
Relative Volume:
1.60
시가총액:
$80.68M
수익:
$525.00K
순이익/손실:
$-44.76M
주가수익비율:
-1.7739
EPS:
-0.6652
순현금흐름:
$-37.46M
1주 성능:
-20.27%
1개월 성능:
-29.34%
6개월 성능:
-51.04%
1년 성능:
-68.11%
1일 변동 폭
$1.16
$1.32
1주일 범위
$1.16
$1.635
52주 변동 폭
$1.16
$4.555
Cardiff Oncology Inc Stock (CRDF) Company Profile
명칭
Cardiff Oncology Inc
전화
858-952-7570
주소
11055 FLINTKOTE AVENUE, SAN DIEGO, CA
Compare CRDF vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CRDF
Cardiff Oncology Inc
|
1.18 | 97.09M | 525.00K | -44.76M | -37.46M | -0.6652 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Cardiff Oncology Inc Stock (CRDF) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-05 | 개시 | Noble Capital Markets | Outperform |
| 2025-07-08 | 개시 | Ladenburg Thalmann | Buy |
| 2025-06-24 | 개시 | Jefferies | Hold |
| 2024-09-06 | 개시 | Craig Hallum | Buy |
| 2022-01-05 | 개시 | William Blair | Outperform |
| 2021-12-08 | 개시 | Robert W. Baird | Outperform |
| 2021-08-09 | 재개 | Maxim Group | Buy |
| 2020-10-22 | 개시 | H.C. Wainwright | Buy |
| 2020-10-08 | 개시 | Piper Sandler | Overweight |
모두보기
Cardiff Oncology Inc 주식(CRDF)의 최신 뉴스
Cardiff Oncology (CRDF) director receives 40,565 stock options grant - Stock Titan
Cardiff Oncology (CRDF) director receives grant of 40,565 stock options at $1.59 - Stock Titan
Cardiff Oncology Shareholders Approve Directors and Equity Plan - TipRanks
Cardiff Oncology (CRDF) shareholders back board, auditor and equity plan - Stock Titan
Cardiff Oncology (CRDF) Holds Steady at $1.50 as Key Levels Define Trading RangeProtective Put - newsline.com
Cardiff Oncology, Inc. (CRDF) Discusses Updated Phase II CRDF-004 Data on Onvansertib in First-Line RAS-Mutated Metastatic Colorectal CancerSlideshow (NASDAQ:CRDF) 2026-06-07 - Seeking Alpha
Lucid Capital Maintains Cardiff Oncology(CRDF.US) With Buy Rating, Cuts Target Price to $4 - Moomoo
CRDF Technical Analysis | Trend, Signals & Chart Patterns - ChartMill
Cardiff Oncology Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
Craig-Hallum Maintains Cardiff Oncology(CRDF.US) With Hold Rating, Maintains Target Price $2 - Moomoo
Cardiff Oncology (CRDF) Faces Downgrade Amid Phase II Study Upda - GuruFocus
CRDF Downgraded by Craig-Hallum -- Price Target Lowered to $2.00 - GuruFocus
Cardiff Oncology (CRDF) Faces Downgrade Amid Phase II Study Update - GuruFocus
Cardiff Oncology unveils promising Phase 2 onvansertib data - TipRanks
Onvansertib Phase 2 results move Cardiff Oncology (NASDAQ: CRDF) toward Phase 3 - Stock Titan
Cardiff Oncology Inc Call on Updated Phase 2 CRDF-004 Transcript - GuruFocus
Cardiff Oncology (CRDF) Reports Promising Phase 2 Results for On - GuruFocus
Cardiff Oncology reports positive phase 2 trial results for onvansertib By Investing.com - Investing.com Australia
Cardiff Oncology reports positive phase 2 trial results for onvansertib - Investing.com
Cardiff Oncology Announces Positive Phase 2 Trial Results for Onvansertib in RAS-Mutated Metastatic Colorectal Cancer, Plans Registrational Study - Quiver Quantitative
Cardiff Oncology Announces Presentation Of Positive Results From Its Randomized, Controlled Phase 2 Trial Of Onvansertib In First-Line RAS-Mutated mCRC At The 2026 ASCO Annual Meeting - TradingView
Cardiff Oncology Announces Presentation of Positive Results from its Randomized, Controlled Phase 2 Trial of Onvansertib in First-Line RAS-Mutated mCRC at the 2026 ASCO Annual Meeting - The Manila Times
Cardiff Oncology to Participate in the Jefferies Global Healthcare Conference - The Manila Times
Clinical-stage biotech CEO in Jefferies health conference fireside chat - Stock Titan
Cardiff Oncology Shares Fall After HC Wainwright, TD Cowen Downgrades - marketscreener.com
CRDF Downgraded by TD Cowen -- Rating Changed to Hold - GuruFocus
CRDF Downgraded by HC Wainwright & Co. -- Rating Changed to Neut - GuruFocus
Cardiff Oncology (CRDF) Files Lawsuit Against Nerviano Medical S - GuruFocus
TD Cowen Downgrades Cardiff Oncology to Hold From Buy - Moomoo
H.C. Wainwright cuts Cardiff Oncology stock rating on license termination By Investing.com - Investing.com Canada
TD Cowen downgrades Cardiff Oncology stock rating on license dispute By Investing.com - Investing.com Canada
This Craig-Hallum Analyst Turns Bearish; Here Are Top 5 Downgrades For Monday - Sahm
Cardiff Oncology, Inc. 8-K Filing Details for May 27, 2026: Company Information, NASDAQ Listing, and Key Disclosures - Minichart
Cardiff OncologyNms Informs Cardiff Oncology Of Agreement Termination On May 27, 2026 - TradingView
[8-K] Cardiff Oncology, Inc. Reports Material Event - Stock Titan
Cardiff Oncology 1Q Loss/Shr 18c >CRDF - Moomoo
Cardiff Oncology (CRDF) Hovering Near Support as Modest Decline ExtendsRounding Top - newsline.com
CRDF: First Quarter 2026 Results - Zacks Small Cap Research
Cardiff Oncology to host webcast on cancer trial data By Investing.com - Investing.com South Africa
Cardiff Oncology to host webcast on cancer trial data - Investing.com UK
New colorectal cancer trial data heads to ASCO, investor webcast June 3 - Stock Titan
Cardiff Oncology Announces Webcast to Discuss Updated Phase - GlobeNewswire
Cardiff Oncology sues Nerviano as analyst backs Onvansertib defense - MSN
Cardiff Oncology Sues Nerviano As Analyst Backs Onvansertib Defense - Benzinga
Cardiff Oncology And 2 Other Promising Penny Stocks For Your Watchlist - Yahoo Finance
Cardiff Oncology Files Lawsuit Over Onvansertib Patent Rights - TipRanks
Cardiff Oncology, Inc. (CRDF) has filed documents with the U.S. Securities and Exchange Commission (SEC), disclosing that it has initiated a lawsuit against Nerviano Medical Sciences, accusing the latter of breaching the licensing agreement regarding the in - Bitget
Cardiff Oncology Inc (CRDF) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Cardiff Oncology Inc 주식 (CRDF) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| PACE GARY W | Director |
Jul 30 '25 |
Buy |
2.45 |
15,000 |
36,750 |
1,345,676 |
2.60%
0.94%
자본화:
|
볼륨(24시간):